NKG2D is a NK cell receptor expressed by all human CTLs ( 1 ) that recognizes MHC class Irelated chain (MIC) and UL-16 -binding protein (ULPB) molecules expressed on stressed and transformed target cells ( 1 -3 ) . NKG2D has been implicated in antitumor immunity mediated by both NK cells and CTLs ( 4, 5 ) and in T cell-mediated immune disorders such as celiac disease ( 6, 7 ) , rheumatoid arthritis ( 8 ) , and NOD mouse model for juvenile type 1 diabetes ( 9 ) . In humans, NKG2D associates exclusively with DAP10 ( 6, 10 -12 ) , an adaptor with a YINM cytoplasmic tail motif that activates phosphatidylinositol 3-kinase (PI3-K) ( 10 ), but not the syk/ZAP-70 kinase family. Because of these similarities with the CD28 signaling pathway, NKG2D-DAP10 was initially thought to function mainly as a co-stimulator ( 1 ) and to play a role in autoimmunity by promoting activation of autoreactive T cells. However, several studies indicate that NKG2D-DAP10 in human can also mediate cytolysis independently of TCR engagement in eff ector CTLs exposed to IL-15 or high doses of IL-2 ( 6, 13, 14 ) . This layer of eff ector T cell regulation by NKG2D at the level of cytolysis may serve to eff ectively and rapidly eliminate infected or transformed target tissue cells independently of antigen specifi city, and may participate in aberrant tissue destruction in diseases in which IL-15 expression is dysregulated (for review see reference [ 15 ] ).
The downstream co-stimulatory and cytolytic signaling pathways recruited by NKG2D in CTLs remain incompletely characterized. Intriguingly, several studies suggest that cPLA 2 may be involved in infl ammatory and autoimmune diseases ( 16 -18 ) . However, how cPLA 2 drives immunopathological processes and whether it involves CTLs is poorly understood. not control siRNA. In contrast, TCR-mediated cytolysis remained essentially intact for this level of specifi c cytolysis ( Fig.  1 B , middle) . The level of inhibition observed for NKG2D-mediated cytolysis was highly signifi cant considering that some residual cPLA 2 could be detected ( Fig. 1 B , left) . Second, similar results were obtained when using MIC + C1R target cells ( Fig. 1 D ) . Importantly, addition of AA ( Fig. 1 D ) , but not a control polyunsaturated fatty acid, linoleic acid (LA), rescued NKG2D-mediated cytolysis ( Fig. 1 D , right) . The assays were performed either with global unsorted siRNA-transfected CTLs ( Fig. 1, B and D , right), or with CTLs sorted into GFP + -transfected and GFP Ϫ -untransfected CTLs ( Fig. 1 D , middle) .
Having shown that cPLA 2 played a role in NKG2D-mediated cytolysis, we wanted to more specifi cally demonstrate its role in the release of cytolytic granules. We previously reported, that ligation of NKG2D receptors expressed on CTLs with monoclonal anti-NKG2D mAb triggered granule release using a BLT esterase assay ( 6 ) . As anticipated, knock down of cPLA 2 by siRNA ( Fig. 1 C ) blocked degranulation. Similar results were obtained in the presence of the pharmacological inhibitor CF3 (unpublished data). Importantly, cPLA 2 inhibition did not aff ect the level of granzyme and perforin expression in CTLs (Fig. S2 , available at http://www.jem.org/cgi/content/ full/jem.20071887/DC1), further suggesting that cPLA 2 plays a role in NKG2D-mediated degranulation.
Interestingly, cPLA 2 inhibition by AACOCF3 or knock down by siRNA aff ected only marginally TCR-mediated cytolysis ( Figs. 1 and 2 ) .
Altogether, these results demonstrate that cPLA 2 and AA play a critical role in NKG2D-mediated, but not TCR-mediated, cytolytic granule exocytosis in eff ector CTLs. cPLA 2 plays a critical role in NKG2D-mediated cytolytic co-stimulatory functions NKG2D was shown to function as a co-stimulatory receptor that enhances TCR-dependent cytolytic responses ( 13, 29 ) . We therefore investigated whether cPLA 2 was also implicated in NKG2D cytolytic co-stimulatory functions. This study had to be performed in CTLs grown in medium with low IL-2, in which NKG2D was not licensed to mediate direct killing. As previously reported ( 29 ) , NKG2D signifi cantly increased TCR-mediated cytolysis in two distinct PB-CTL clones ( Fig. 2 ) . Importantly, cPLA 2 inhibition prevented NKG2D enhancement of TCR-mediated cytolysis, and AA signifi cantly rescued NKG2D co-stimulation ( Fig. 2 ) . In contrast, cPLA 2 inhibition had little or no signifi cant eff ect on TCR-mediated cytolysis ( Fig. 2 ) .
In summary, these observations also support a role for cPLA 2 in NKG2D cytolytic co-stimulatory functions.
NKG2D induces cPLA 2 activation and AA release in effector CTLs
To establish a biochemical basis for cPLA 2 functions in CTLs, we determined NKG2D-induced cPLA 2 phosphorylation and AA release in several diff erent CTL subsets, including in IE-CTL clones derived from celiac patients. Expression of cPLA 2 in Interestingly, several reports point to a potential role of cPLA 2 in T cell proliferation ( 19, 20 ) . Furthermore, cPLA 2 was shown to be involved in granule exocytosis by neuronal cells ( 21, 22 ) , hormonal cells ( 23 ) , and granulocytes ( 24 -27 ) , suggesting that it might also be implicated in granular release occurring in the context of cytolysis and cytokine secretion in T cells. Finally, cPLA 2 activation by surface receptors is dependent on phosphorylation at Ser 505 by MAP kinases ( 28 ) , and NKG2D induces c-Jun N-terminal kinase (JNK) and extracellular signal -regulated kinase (ERK) activation in CTLs ( 6 ) . Together, these observations prompted us to examine a potential link between cPLA 2 and NKG2D eff ector function in CTLs and its relevance in celiac disease. RESULTS cPLA 2 plays a critical role in direct NKG2D-mediated cytolysis NKG2D is licensed to mediate cytolysis independently of TCR activation in CTLs when they are in an eff ector stage and in the presence of IL-15 or high doses of IL-2 ( 6 ). Importantly, under these conditions it is possible to assess how cPLA 2 aff ects NKG2D eff ector functions independently from other receptors. To determine that our fi ndings were not restricted to a particular subset of eff ector CTLs, we analyzed the eff ect of cPLA 2 inhibition in a variety of eff ector CTLs. Specifi cally, we studied freshly isolated eff ector intestinal intraepithelial CTLs (IE-CTLs) that were prestimulated in vitro with IL-15, normal IE-CTL clones, IE-CTL clones derived from celiac patients, peripheral blood eff ector CTL (PB-CTL) clones, and the leukemia TALL-104 CD8 T cell line. This latter cell line was previously used as a model to study the NKG2D cytolytic signaling pathway ( 6 ) . All clones and cell lines were grown in the presence of a high concentration of IL-2, which is known to substitute for IL-15.
The cPLA 2 inhibitor AACOCF3 (CF3) impaired NKG2D-mediated cytolysis in antibody-redirected cytolytic assays ( Fig. 1 A , left) . Importantly, this fi nding could be extended to cytolytic assays using MIC-transfected C1R cells as targets ( Fig. 1 A , right) . Furthermore, arachidonic acid (AA) signifi cantly restored cytolysis, strongly arguing against a nonspecifi c eff ect of the cPLA 2 inhibitor AACOCF3 ( Fig. 1 A ,  right) . Finally, AACOCF3 and AA had a dose-dependent eff ect on NKG2D-mediated cytolysis in freshly isolated IECTLs (Fig. S1 , available at http://www.jem.org/cgi/content/ full/jem.20071887/DC1).
To further assess the critical role of cPLA 2 in NKG2D-mediated cytolysis and granule release, cPLA 2 was " knocked down " in TALL-104 ( Fig. 1, B and C ) and PB-CTLs ( Fig. 1 B , right) using cPLA 2 small interfering (si)RNA. Importantly, cPLA 2 siRNA specifi cally targeted cPLA 2 expression, as it affected neither ERK nor JNK expression (not depicted) and activation ( Fig. 1 B , left) , nor 5-lipoxygenase (5-LO) expression ( Fig. 1 C , left) . The eff ect of cPLA 2 knock down on NKG2D-mediated cytolysis was assessed in two ways. First, in redirected cytolytic assays, as expected, NKG2D-mediated cytolysis was inhibited by up to 50% in the presence of cPLA 2 siRNA, but
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To further assess the ability of NKG2D to activate cPLA 2 , we studied perinuclear translocation of cPLA 2 and cPLA 2 activity in IE-and PB-CTLs. As anticipated, NKG2D engagement induced perinuclear translocation of cPLA 2 (Fig. S3 A, available at http://www.jem.org/cgi/content/full/jem.20071887/DC1) mature T cells has been controversial ( 19, 30 ) . However, using Western blot analysis, we demonstrated cPLA 2 expression in diff erent eff ector CTLs ( Fig. 3, left) . Furthermore, as shown in Fig. 3 , NKG2D cross-linking induced cPLA 2 phosphorylation in a dose-dependent manner ( Fig. 3, left) . To determine whether the capacity of NKG2D to induce cPLA 2 phosphorylation in CTLs was dependent on their activation status, we sorted freshly purifi ed resting CD8 ␤ + peripheral blood T cells that were used either immediately for biochemical studies or to establish a short-term eff ector CTL line by allogenic stimulation, as previously described ( 31 ) . Interestingly, NKG2D and IL-15 failed to induce cPLA 2 phosphorylation in resting CD8 + TCR ␣ ␤ + peripheral blood lymphocytes, but not in the short-term derived eff ector CTL line (Fig. S4 , available at http://www.jem.org/cgi/content/ full/jem.20071887/DC1). These fi ndings are in accordance with previously reported data ( 6 ) showing that licensing of NKG2D by IL-15 to mediate cytolysis was restricted to CTLs in the eff ector stage.
Finally, we investigated whether induction of cPLA 2 phosphorylation was associated with AA release ( Fig. 3 , right) . This was investigated under conditions of stimulation resulting in and up-regulated cPLA 2 activity (Fig. S3 B) , which were blocked in the presence of the pharmacological inhibitor CF3 (Fig. S3) . Figure 2 . cPLA 2 activation is necessary for NKG2D cytolytic costimulatory functions. Inhibition of cPLA 2 blocks NKG2D augmentation of cytolytic T cell functions and AA reverses this blockage. Co-stimulation of cytolytic T cell functions by NKG2D was studied using three different PB-CTL clones (#411, #414, and #348) that were generated and cultured with low IL-2 (5 U/ml), in which NKG2D does not mediate direct cytolysis. Representative experiments of clone 411(top) and 414 (middle) are shown. PB-CTLs were pretreated with vehicle or CF3. Redirected cytolysis was performed against 51 Cr-labeled FcgR + P815 targets (E/T ratio of 50:1) in the presence of anti-CD3 mAbs at the indicated concentration in combination with either anti-NKG2D mAbs or isotype control IgG1 at fi xed concentration (1 μ g/ml). (bottom) A rescue experiment was performed by adding AA to CF3-pretreated cells 1 h after co-culture with target cells. A summary of three independent experiments for an anti-CD3 mAb concentration of 12.5 ng/ml with means ± SD is shown. P values are from a Tukey-adjusted pairwise comparison. 
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ERK and JNK regulate NKG2D-mediated cytolysis through cPLA 2 activation in CTLs Previous studies had shown that NKG2D activated ERK and JNK through distinct pathways and that both MAP kinases regulated NKG2D-mediated cytolysis in CTLs in an additive manner ( 6 ) . However, how ERK and JNK played a role in cytolysis remained elusive. Interestingly, cPLA 2 activation by surface receptors was shown to be dependent on MAP kinase activation (for review see reference [ 28 ] ). This prompted us maximal levels of cPLA 2 phosphorylation. TCR stimulation induced AA release. However, importantly, NKG2D could induce AA release independently of TCR engagement.
Collectively, these results demonstrate that NKG2D can induce cPLA 2 activation and mediate AA release independently of TCR stimulation. This unexpected function of NKG2D suggests that in tissues expressing stress-induced ligands, CTLs could participate in the activation of granulocytes sensitive to the presence of AA. to investigate whether there was a link between ERK, JNK, cPLA 2 activation, and NKG2D-mediated cytolysis.
We fi rst determined the kinetic of ERK, JNK, and cPLA 2 phosphorylation upon NKG2D stimulation. The peak of cPLA 2 phosphorylation occurred at 10 -15 min after ERK and concomitant with JNKK1 and JNK phosphorylation ( Fig. 4 A ,  top left) . These results suggested that cPLA 2 phosphorylation was downstream of ERK and JNK.
To further evaluate the function of JNK and ERK in cPLA 2 activation and NKG2D-mediated cytolysis, we performed studies with pharmacological inhibitors targeting specifi c MAP kinases. As anticipated, cPLA 2 phosphorylation ( Fig. 4 A , bottom left) and AA release (not depicted) were blocked in an additive manner upon ERK (PD98059) and JNK (SP600125) inhibition. In contrast, the p38 inhibitor SB 203580 had no eff ect (unpublished data), a result that is in agreement with its lack of function in NKG2D-mediated cytolysis ( 6 ) . Finally, addition of AA reversed JNK inhibition, more signifi cantly than ERK inhibition of NKG2D-mediated cytolysis ( Fig. 4 A , right) .
We next dissected the signaling pathway leading to JNK activation and further assessed its critical role in cPLA 2 activation using a dominant-negative and overexpression approach. Vav1, which regulates JNK activation through a Rho/Rac1 → MAPK kinase kinase 1 pathway ( 32 ), was also reported to play an essential role in the NKG2D cytolytic pathway in NK cells ( 33, 34 ) . These observations suggested that Vav1 could control JNK activation. In agreement, our kinetic analysis indicated that Vav1 activation preceded JNKK1 and JNK phosphorylation (compare Fig. 4 , A and B , top left). In addition, a dominant-negative of Vav1, Vav1-C ( 33 ), blocked both JNK and cPLA 2 activation after NKG2D cross-linking in CTLs ( Fig. 4 B , top right) . To further assess the role of JNK in cPLA 2 phosphorylation, TALL-104 CTLs were transfected with a dominant-negative JNKK2, which was shown to prevent JNK activation. As anticipated, blocking JNK activation resulted in inhibition of cPLA 2 phosphorylation upon NKG2D engagement ( Fig. 4 B , bottom left). Conversely, simple overexpression of constitutive active JNK (JNKK2-JNK1), but not inactive JNK (JNKK2[KM]-JNK1) ( 35 ) , induced similar levels of cPLA 2 phosphorylation than NKG2D stimulation in CTLs ( Fig. 4 B ,  bottom right) .
Finally, because the upstream events leading to ERK activation were defi ned by a previous study ( 6 ) (see also Fig. 7 ) , we focused on assessing the role of ERK in cPLA 2 activation. As predicted by the pharmacological studies, the dominantnegative of MEK-1 (MEK-2A) ( 36, 37 ) , which is located upstream of ERK, blocked ERK and cPLA 2 phosphorylation ( Fig. 4 C , left) , whereas overexpression of constitutive active MEK-1 (MEK-2E) ( 36, 37 ) , induced cPLA 2 phosphorylation ( Fig. 4 C , right) .
Altogether, these observations suggest that Vav is upstream of JNK, and that JNK and ERK control NKG2D-mediated cPLA 2 activation in CTLs in an independent and additive manner. inspection and background staining, automatic image analysis was performed using the ACIS software (see Materials and methods) as previously described ( 39, 40 ) . Specifi c cPLA 2 staining appears in red when staining is above background threshold values after overlay ( Fig. 6 A ) . Importantly, the IL-15 arms NKG2D to mediate cytolysis and AA release in primary IE-CTLs by up-regulating cPLA 2 
expression and activation
We had previously demonstrated that IL-15 or high levels of IL-2 (which can substitute for IL-15) licensed NKG2D to mediate cytolysis independently of TCR activation in eff ector CTLs ( 6, 13 ) . Furthermore, we showed that IE-CTLs exposed in vivo to IL-15 in active celiac disease killed MIC + target cells ( 6 ) . Here, we investigated whether the licensing of NKG2D to mediated direct cytolysis in freshly purifi ed IE-CTLs involved cPLA 2 activation by IL-15. We fi rst determined whether IL-15 could activate cPLA 2 . Interestingly, IL-15 induced not only ERK and JNK phosphorylation, as previously shown ( 6, 38 ) , but also cPLA 2 phosphorylation ( Fig. 5 A , left) . The time course was similar to that of NKG2D (compare Fig. 5 A , left, and Fig.  4 A , left) . In addition, cPLA 2 expression was increased in primary IE-CTLs stimulated for 48 h with IL-15, but not with IL-7 ( Fig. 5 A , right) . Furthermore, IL-15 synergized with NKG2D to induce cPLA 2 phosphorylation in a dose- ( Fig. 5 B , left) and time-dependent manner ( Fig. 5 B , right) . cPLA 2 activity was signifi cantly up-regulated only in freshly isolated IECTLs that were prestimulated with IL-15 for 48 h. Importantly, induction of cPLA 2 activity paralleled the ability of NKG2D to mediate degranulation (compare Fig. 5, C and D ) . Conversely, cPLA 2 inhibition blocked cPLA 2 activity ( Fig. 5 C ) and degranulation ( Fig. 5 D ) , which was restored in the presence of AA ( Fig. 5 D ) .
We next investigated whether NKG2D could induce AA release in primary eff ector IE-CTLs. As shown in Fig. 5 E , IL-15 and NKG2D independently induced AA release. The release was maximal when IE-CTLs were stimulated simultaneously by IL-15 and NKG2D. Importantly, AA release was also observed upon engagement of NKG2D by plate-coated monoclonal anti-NKG2D mAb ( Fig. 5 E , left) and MIC-expressing EL4 fi broblasts ( Fig. 5 E , right) .
Altogether, these observations suggest that priming of the NKG2D cytolytic pathway by IL-15 in primary eff ector CTLs entails up-regulation of cPLA 2 expression and activation. Furthermore, IL-15 and NKG2D can induce AA release.
Expression of phosphorylated cPLA 2 in IE-CTLs of celiac patients NKG2D and IL-15 were shown to play a critical role in celiac disease by licensing IE-CTLs to kill enterocytes ( 6 ). Furthermore, previous studies in active celiac patients reported that ERK ( 6 ) and JNK ( 38 ) phosphorylation were induced in IE-CTLs of active celiac patients. Together, these observations suggested that cPLA 2 might be activated in IE-CTLs of celiac patients.
In situ analysis of immunohistochemical staining with anti-CD3 antibody in combination with anti-phospho-cPLA 2 antibody or control antibody revealed that the frequency of IE-CTL -expressing phospho-cPLA 2 was highly increased in celiac patients ( n = 6; 79 ± 8%) compared with controls ( n = 4; 13 ± 4.6%; P = 0.001) ( Fig. 6 B ) . In addition, to control for evaluation bias inherent to subjective morphological + IE-CTLs ± SD is presented after manual and automated count. For manual count, four control and six celiac patients were analyzed. For automated count, > 100 IE-CTLs in two control and two celiac slides were analyzed. P value was determined with the exact Wilcoxon rank sum test. Note that manual and automated count give similar percentage of phospho-cPLA 2 + IE-CTLs.
cule associated with NKR-P1A remains undefi ned. Thus, the role of cPLA 2 could not be ascribed to particular cytolytic signaling pathways and to individual NK receptors in human. Our study unambiguously identifi es the NKG2D-DAP10 in human CTLs as an immunoreceptor complex that requires cPLA 2 activation and AA release as integral components of its cytolytic machinery. In addition, our preliminary data indicate that this fi nding is not limited to CTLs, because the NKG2D cytolytic pathway in NK cells also involves cPLA 2 activation (unpublished data). Interestingly, our data suggest that cPLA 2 is not signifi cantly involved in TCR-mediated cytolysis. Future studies will determine whether, more generally, ITAM-signaling receptors mobilizing high levels of calcium mediate granule exocytosis independently of cPLA 2 . In agreement, NK cell receptors associated with ITAM-bearing adaptor molecules induce high levels of calcium fl ux ( 47 ) and cPLA 2 -independent cytolysis ( 56 ). Importantly, however, even though cPLA 2 is not directly involved in TCR-mediated cytolysis, it plays a critical role in the co-stimulation of cytolytic T cell responses. Notably, automatic count confi rmed the manual count by showing a similar signifi cant increase in the percentage of cPLA 2 -positive IE-CTLs ( Fig. 6 B ) . This result is even more striking in regard to the augmentation in the number of IE-CTLs in celiac disease, reaching classically up to 10 times the value of that observed in normal controls ( 41 ) . The total number of IE-CTL -expressing phospho-cPLA 2 in celiac patients can therefore be estimated to be 40 -60-fold higher than in controls. This fi nding is particularly relevant in the context of our observations that cPLA 2 plays a critical role in NKG2D cytolytic functions of celiac and IL-15 -stimulated IE-CTLs ( Figs. 1 and 5 ) . Furthermore, phospho-cPLA 2 , similar to phospho-ERK and JNK ( 6, 38 ) , was also highly up-regulated in enterocytes of celiac patients ( Fig. 6 A ) , especially in the nuclear compartment (not depicted) where accumulation correlates with activation (for review see reference [ 28 ] ).
Altogether, these results illustrate that cPLA 2 is activated in IE-CTLs of active celiac patients and support, in association with other present ( Figs. 1 and 5 ) and past ( 6 ) observations, an in vivo role for cPLA 2 in celiac disease pathogenesis.
DISCUSSION
Our study establishes an unexpected connection between Il-15-and CTL-mediated immunopathology in celiac disease and infl ammatory lipid biology. Our observations also suggest that NKG2D eff ector functions, particularly cytolysis, are critically regulated by cPLA 2 in CTLs. Furthermore, we identify an unexpected role for Vav, JNK, and ERK in NKG2D-mediated cytolysis by showing that they mediate cPLA 2 activation. Finally, our study suggests that NKG2D and IL-15 could contribute to tissue infl ammation and granulocyte activation by promoting the release of AA in CTLs ( Fig. 7 ) .
The molecular basis for exocytosis is a fi eld of high investigation. It involves traffi cking of granules to the plasma membrane and membrane fusion events. There is increasing evidence that exocytosis can be triggered, either under conditions of high-level calcium mobilization suffi cient to activate snare-mediated membrane fusion (for review see references [ 42 ] ), or under conditions of low levels of calcium mobilization ( 43 ) involving AA and its eicosanoids metabolites, which are known as fusogens ( 44 ) . This latter mechanism is thought to play a role in neutrophil and neuroendocrine cell degranulation ( 45, 46 ) . It may be particularly relevant for surface receptors that, similar to NKG2D, signal through an adaptor molecule lacking an ITAM motif ( 10 ) , and induce relatively low levels of calcium ( 34 , 47 ) (Fig. S5 , available at http://www.jem.org/cgi/content/full/jem.20071887/DC1). Pharmacological studies performed in the 1980s ( 48 -52 ) suggested that infl ammatory lipid mediators may play a role in NK cell -mediated lysis in human and rodents without defi ning the receptors involved ( 48 -52 ) . More recently, cPLA 2 was proposed to contribute to NKR-P1A -induced cytolysis in rat NK cells ( 53 ) . However, recent fi ndings in human indicate that engagement of NKR-P1A by its ligand LLT1 ( 54, 55 ) inhibited rather than induced NK cell -mediated lysis ( 54 ) . Furthermore, the nature of the adaptor mole- Figure 7 . Model of the NKG2D signaling pathway in CTLs. The NKG2D cytolytic signaling pathway involves PLC-␥ 2, Vav1, and PI3-K activation ( 60 ) . How these upstream signaling events are interconnected in CTLs remains to be determined. NKG2D-mediated cytolysis requires activation of cPLA 2 and AA release, suggesting that the level of calcium mobilization achieved upon NKG2D cross-linking is insuffi cient to allow membrane fusion events and exocytosis. Cytosolic PLA 2 activation itself is mediated through two independent pathways, Vav-1 → JNKK1/2 → JNK1/2 → cPLA 2 and PI3-K → MEK1/2 → ERK → cPLA 2 . It is likely that these pathways also promote granule polarization ( 62, 63, 67 ) . In addition, cPLA 2 activation is also required for NKG2D cytolytic co-stimulatory functions. Interestingly, IL-15, which licenses NKG2D killing in CTLs ( 6 ), enhances NKG2D-mediated JNK, ERK and cPLA 2 phosphorylation, and AA release. Once released, AA can potentially be reincorporated into phospholipids, mediate the biosynthesis of eicosanoids and induce granulocyte activation.
expression, and activation of the PI3-K → ERK signaling pathway ( 6 ) . We now show that IL-15 is also involved in the activation of JNK. More importantly, we demonstrate that IL-15 -mediated licensing of the NKG2D cytolytic pathway requires cPLA 2 activation, and that cPLA 2 is highly activated in IE-CTLs of active celiac patients. Interestingly, cPLA 2 is concomitantly activated in the intestinal epithelial cells. This activation of cPLA 2 may be secondary to the activation of enterocytes by IL-15 ( 74 ) and/or AA released by IE-CTLs.
Finally, our study reveals that NKG2D and IL-15 signaling in eff ector CTLs causes CTLs to release AA and potentially eicosanoids, such as leukotrienes and prostaglandins. Eicosanoid synthesis by CTLs is supported by our fi ndings that NKG2D induces AA production and activates 5-LO and COX (unpublished data). Interestingly, AA and eicosanoids favor granulocyte recruitment and activation ( 75 -79 ) . These fi ndings establish an unrecognized link between CTLs, NKG2D, IL-15, and infl ammation, which may have as of yet unrecognized patho lo gical implications. In particular, it may be relevant in immune-mediated diseases, such as rheumatoid arthritis and celiac disease, where NKG2D and IL-15 play a pathogenic role (for review see reference [ 15 ] ) and where granulocytes are activated ( 80 -84 ) .
Collectively, our fi ndings invite us to reexamine the role of IL-15 and NKG2D in infl ammation and autoimmunity, and develop therapeutic strategies aimed at blocking cPLA 2 in diseases associated with dysregulated IL-15 expression and NKG2D activation. Future studies will determine whether 5-LO and COX should also be targeted. Our preliminary observations suggest that 5-LO, but not COX, is involved in NKG2D-mediated immunopathology. In addition, in view of observations suggesting that prostaglandins inhibit NK cell cytolytic responses ( 85, 86 ) , blocking COX activation may even be deleterious.
MATERIALS AND METHODS
Human subjects. For immunohistochemical studies, six adult patients with active celiac disease and four control aged-matched individuals undergoing biopsies for functional intestinal disorders of nonceliac origin were studied. Diagnosis of celiac disease was based on detection of antitransglutaminase antibodies, the presence of HLA DQ2 or DQ8, villous atrophy, and clinical and histological response to a gluten-free diet. In addition, IE-CTLs were isolated from surgical specimens of individuals undergoing gastric bypass for morbid obesity, as previously described ( 6 ). All subjects gave written informed consent and research was approved by the University of Chicago Institutional Review board.
CTL isolation and cell culture. IE-CTLs were purifi ed from jejunal biopsies and surgical specimens, as previously described ( 31 ) . Intraepithelial and peripheral blood NKG2D + TCR + CD8 + CTL lines and clones were obtained and cultured as previously described ( 31 ) . PB-CTL clone #348 and #414 (cultured with 5 U/ml of IL-2) in which NKG2D exerts co-stimulatory cytolytic functions but cannot induce direct cytolysis were obtained and cultured, as previously described ( 1, 8 ) . Resting peripheral blood CD8 + TCR ␣ ␤ + T lymphocytes were purifi ed and an eff ector CTL line was generated according to a previously described protocol ( 6, 31 ) . In brief, peripheral blood lymphocytes were isolated from whole blood of healthy volunteers after Ficoll density gradient centrifugation (GE Healthcare). Cells were stained with anti-CD8 ␤ APC-conjugated mAb (BD) and purifi ed by AutoMACS (Miltenyi NKG2D was unsuccessful to induce cPLA 2 phosphorylation in resting CD8 + TCR ␣ ␤ + peripheral blood lymphocytes. This fi nding may explain why NKG2D fails to exert costimulatory function in resting noneff ector CD8 T cells ( 57 ) . Together, these observations are in agreement with the general concept, reported by Bryceson et al. ( 58, 59 ) that receptors using diff erent adapters and signaling pathways contribute distinctively and synergistically to cytolysis.
Studies had identifi ed PLC-␥ 2, PI3-K, and Grb2/Vav1 as key upstream signaling molecules of the NKG2D cytolytic pathway ( Fig. 7 ) ( 33, 60, 61 ) . Our previous analysis of the human NKG2D-DAP10 cytolytic signaling pathway suggested that ERK and JNK, activated through independent pathways, played critical roles in NKG2D-but not TCR-mediated cytolysis ( Fig. 7 ) ( 6 ) . The role of PI3K in cytolysis is complex and remains incompletely understood; among its potential roles, PI3K is thought to be involved in ERK activation ( 6, 62, 63 ) . A critical role for Vav in natural killer signaling and cytotoxicity has been reported in mouse and human by several groups ( 33, 64 -68 ) . Vav is thought to play a role similar to that of ERK ( 62, 63 ) in cytolysis by promoting granule polarization ( 67 ) . This study reveals that Vav1 is upstream of JNK in the NKG2D cytolytic pathway ( Fig. 7 ) . More importantly, it sheds a new light on the role of the PI3K -ERK and Vav -JNK pathways in NKG2D-mediated cytolysis by showing that ERK and JNK critically regulate cPLA 2 activation, which in turn critically regulates NKG2D-mediated degranulation and cytolysis ( Fig. 7 ) . Whether AA, which is released upon cPLA 2 activation, plays a role in granule exocytosis as fusogen ( 22, 44, 45 ) or indirectly through its role in the biosynthesis of eicosanoids remains to be determined. AA serves as a substrate to 5-LO and cyclooxygenase (COX), which drive the leukotriene and prostaglandin synthesis pathways, respectively ( 28 ) . Interestingly, although NKG2D engagement induces 5-LO and COX activation, only 5-LO is involved in NKG2D-mediated cytolysis (unpublished data). These observations are in agreement with reports suggesting that leukotrienes, but not prostaglandins, play a role in lymphokine-activated killer activity ( 51, 52 ) and NK-mediated cytolysis ( 69, 70 ) .
Convergent observations suggest that IL-15 and NKG2D may coordinately regulate CTL eff ector functions and mediate organ-specifi c immunopathology (for review see reference [ 15 ] ). For instance, the role of NKG2D as a direct mediator of cytolysis was shown in celiac disease ( 6 ) . Celiac disease is an infl ammatory intestinal disorder with an autoimmune component triggered by dietary gluten in genetically susceptible individuals ( 71, 72 ) . Although the role of gluten-specifi c, DQ2-or DQ8-restricted CD4 T cells in the lamina propria was accepted early on ( 73 ) , the role of IE-CTLs was questioned because no gluten-specifi c IE-CTLs could be identifi ed (for review see reference [ 71 ] ). Our fi nding that IL-15 primed NKG2D in CTLs to kill MIC-expressing enterocytes in celiac disease ( 6, 13 ) provided an explanation as to how IECTLs could cause intestinal damage and malabsorption, despite their inability to recognize gluten. Licensing by IL-15 was shown to involve up-regulation of NKG2D and DAP-10 the indicated antibodies, followed by HRP-conjugated goat anti -mouse (HRP-GAM) or donkey anti -rabbit (HRP-DAR) antibodies (Jackson Immunoresearch Laboratories) using the enhanced chemiluminescence (ECL) kit from GE Healthcare. Tyrosine-phosphorylated Vav1 was revealed by antiphosphotyrosine (4G10) antibody after immunoprecipitation of the cell lysates with rabbit polyclonal anti-Vav1 antibody.
Cytotoxicity assay. Chromium release assays were performed as previously described using P815 cells (a Fc ␥ + mouse mastocytoma; American Type Culture Collection), C1R-MICA1, EL4-MICA1, control C1R transfectants, and control EL4 cells at the indicated E:T ratio in triplicate wells ( 6 ) . For Fc-dependent redirected cytotoxicity, eff ectors and targets were incubated in the presence of soluble anti-NKG2D or anti-CD3 mAbs at the indicated concentration. Chromium release was measured using a scintillation counter (Packard). Maximum release was determined by the addition of detergent (10% SDS) and spontaneous release ranged from 5 -10% of the maximum. The percentage of specifi c cytotoxicity was calculated using the formula 100 × (cpm experimental Ϫ cpm spontaneous)/ (cpm maximum Ϫ cpm spontaneous). When indicated, eff ector cells were treated for 30 min before and during the cytotoxic assay with diff erent inhibitors, lipid mediators, or equivalent concentrations of the DMSO or ethanol vehicles.
AA release assay. 10 6 cells/ml IE-CTLs, PB-CTLs, and TALL-104 CTLs were labeled with 0.2 μ Ci 3 H AA (specifi c activity 62.5 Ci/mmol; PerkinElmer) in RPMI 1640 or IMDM with 0.2% fetal bovine serum at 37 ° C 5% CO 2 for 1 or 8 h. After labeling, cells were washed at least three times to remove free 3 H AA and, when indicated, pretreated with inhibitors or vehicles for 30 min in medium with 0.2% bovine serum albumin (BSA). Cells were then incubated with anti-NKG2D, anti-CD3 mAbs, or mouse IgG1 control at 37 ° C for 4 min followed by F(ab') 2 goat anti -mouse IgG for 1 h in medium with 0.2% BSA. Supernatants and cell pellets were separately collected by centrifugation. 3 H AA was measured with a scintillation counter. Percentage of 3 H AA release was calculated as supernatant 3 H/(supernatant 3 H + pellet 3 H) × 100.
Flow cytometric analysis. For surface staining, cells were incubated with fl uorochrome-conjugated antibodies according to standard protocols. Fluorescence was analyzed on a six-color FACSCanto (Becton Dickinson) with quadrants set to score as negative > 99% of control Ig-stained cells.
Measurement of granule release by BLT esterase assay. Granule release was evaluated as previously described ( 6 ) . In brief, CTLs were suspended in RPMI medium containing 2% FCS, incubated in 96-well with 4 μ g/100 μ l of anti-NKG2D mAb or isotype control for 4 min, and then stimulated for 4 h with goat anti -mouse IgG F(ab ' ) 2 at 37 ° C. Maximum granule release was determined using 1% Triton X-100. The supernatants were evaluated for esterase secretion using a standard N-benzyloxycarbonyl lysine thiobenzyl ester (BLT; Calbiochem). The percentage of BLT esterase activity was calculated using the following equation: (experimental BLT esterase release Ϫ spontaneous BLT esterase release)/(maximum BLT esterase release Ϫ spontaneous BLT esterase release) × 100. cPLA 2 enzyme activity assay. cPLA 2 activity was assessed in lysates of primary IE-CTL, PB, and IE-CTL lines according to the manufacturer ' s procedure (Cayman Chemical), as reported ( 87 ), using arachidonoyl thio-PC as a synthetic substrate. In brief, 4 × 10 6 cells were stimulated with anti-NKG2D or isotype control, and the pellets were lysed by three cycles of freeze thawing in lysis buff er (50 mM Hepes, pH 7.4, containing 1 mM EDTA, 1 μ g/ml leupeptin, 5 μ g/ml aprotinin, 1 mM PMSF, 2 mM Na 3 VO 4 , 2.5 mM NaF, and 1 mM DTT). 10 μ l sample supernatant and 5 μ l assay buffer were well mixed and the reaction was initiated by adding 200 μ l substrate solution to the wells. After 1 h incubation at room temperature, 10 μ l of DTNB/EGTA was added to each well to stop the reaction. Absorbance was measured at 414 nm. cPLA 2 activity was expressed as the percentage of Biotec) using anti-APC magnetic beads (Miltenyi Biotec). Purity ( > 95%) of isolation was confi rmed by fl ow cytometry. Purifi ed CD8 + TCR ␣ ␤ + T cells were divided into two parts. One part was directly used for cPLA 2 signal transduction experiments. The other part was used to generate a short-term eff ector CTL line by allogenic stimulation, as previously described ( 31 ) , to investigate whether the eff ector status impacted on the ability of NKG2D to induce cPLA 2 phosphorylation.
MICA-transfected (C1R-MIC) or control vector -transfected (C1R-Neo) C1R cells and CD8 + TCR ␣ ␤ + cytotoxic leukemia TALL-104 cell line (American Type Culture Collection) were cultured, as previously described ( 6 ) . EL4 (American Type Culture Collection TIB-39) are a murine T lymphoma cell line. MICA-transfected EL4 (EL4-MICA) and control EL4 cells were grown in RPMI 1640 supplemented with 10% FCS, glutamine, antibiotics, and G 418.
Reagents, antibodies, and recombinant cytokines. cPLA 2 inhibitor AACOCF3, MEK1/2 inhibitor PD98059, and JNK inhibitor SP600125 were obtained from Calbiochem. AA and LA were obtained from Sigma-Aldrich. Anti-CD3 (clone UCHT1, IgG1) and anti-NKG2D mAbs (clone 1D11, IgG1) and isotype-matched control IgG1 were purchased from BD; PE-conjugated anti-NKG2D 1D11 was purchased from eBioscience; and anti-Vav1, -cPLA 2 , -ERK, -JNK-phospho-cPLA 2 , -phospho-JNKK1, -phospho-PLC ␥ 2, -phospho-ERK, and -phospho-JNK antibodies were purchased from Cell Signaling Technology. Antiphosphotyrosine mAb 4G10 was obtained from Millipore. Antiactin mAb was purchased from Sigma-Aldrich. Anti -5-LO mAb was obtained from Fitzgerald Industries Int. F(ab ' ) 2 goat anti -mouse antibodies were obtained from Jackson ImmunoResearch Laboratories. Human IL-15 and IL-2 were purchased from BD. ( 36, 37 ) . Expression vectors encoding JNKK2-JNK1 (which encodes a constitutively active form of JNK), JNKK2(K149M)-JNK1 (a kinase-defi cient mutant), and JNKK2(KM) have been previously described ( 35 ) . cPLA 2 , 5-LO, and control synthesized siRNA oligonucleotides were purchased from Santa Cruz Biotechnology, Inc. TALL-104 CTL cells were electroporated with the Amaxa Nucleofector (Amaxa, Inc.), using Amaxa Cell Line nucleofection solution V and program T-20. Cells were cultured for 24 -72 h before being used for experiments. For overexpression experiments involving HA-tagged JNKK2-JNK1, HA-tagged JNKK2(KM)-JNK1, or MEK(2E), TALL-104 CTLs were cotransfected with the indicated plasmids and GFP plasmid at a 5:1 ratio. 40 h after transfection, cells were sorted by fl ow cytometry into GFP + and GFP Ϫ cells with FACSAria (BD) before being analyzed for p-cPLA 2 , p-JNK, and p-ERK expressions by Western blot. For siRNA experiments, 4 × 10 6 cells were transfected with 120 pmol siRNA and 30 pmol GFP plasmid. On average, 40% of cells were transfected based on GFP expression. Effi ciency and specifi city of protein knock-down was assessed by Western blot with the appropriate antibodies.
Cell signaling. To look at cPLA 2 , JNK, and ERK phosphorylation, cells were serum-starved for 30 h. To test the eff ects of kinase inhibitors, cells were preincubated for 30 min at 37 ° C with the indicated inhibitors before stimulation. To cross-link immunoreceptors, cells were incubated for 4 min at 4 ° C with the indicated monoclonal antibody before adding F(ab' ) 2 GAM for the indicated duration at 37 ° C. Cells were lysed for 20 min in ice-cold lysis buff er containing fresh protease and phosphatase inhibitors (50 mM Tris-Hcl [pH 7.5]; 150 mM NaCl; 1% Triton-X100; 1 mM EDTA; 1 mM Na 3 VO 4 ; 1 mM NaF; and protease inhibitor cocktail tablets). Cellular debris was removed by centrifugation at 15,000 rpm for 20 min at 4 ° C. Total lysates were subjected to SDS-PAGE electrophoresis and transferred to PVDF membranes (Bio-Rad Laboratories). Proteins were then detected by using Immunohistochemistry and image analysis. Immunohistochemical double staining for CD3 and phospho-cPLA 2 was performed on 4 μ M 10% formalin-fi xed paraffi n sections using the double staining blocking kit (DAKO). Monoclonal anti-CD3 antibody was used at 1:200 dilution (BioGenex), and rabbit polyclonal anti -p-cPLA 2 and isotype antibody were used at 1:50 dilution.
To control for evaluation bias inherent to subjective morphological inspection and background staining, automatic image analysis with the pixel and cell/object-based image analysis was performed using ACIS software from Clarient, as previously described ( 39, 40 ) . For each slide, 5 -6 areas were scanned at 200 × magnifi cation to yield high-resolution digital images. The ACIS software applies the color-specifi c thresholds confi gured by an experienced user-pathologist (MT) to diff erentiate specifi c blue phospho-cPLA 2 staining within lymphocytes and epithelial cells from the surrounding blue background staining. The same threshold values for specifi c blue staining were applied to both control and active celiac biopsy sections. The overlay tool was used to highlight phospho-cPLA 2 -positive areas (defi ned by blue staining above background) in red color within the CD3 + (brown) intraepithelial lymphocyte population ( Fig. 6 ) . From each digital image, at least 100 IE-CTLs were selected and numbered for analysis of phospho-cPLA 2 staining. All cells were classifi ed as either double positive or only CD3 positive (phospho-cPLA 2 negative). Results obtained by software analysis were compared with cell counts obtained by manual morphological inspection.
Statistical analysis.
Mixed eff ects models were constructed for all bar graphs in the fi gures. The treatment variable was included as a fi xed predictor. Experimental plate was included as a random predictor in the model. The outcome variable (specifi c lysis) was log transformed after checking normality of the residuals from the mixed model. Tukey-adjusted pairwise comparisons are reported unless otherwise noted. The main eff ect of treatment was statistically signifi cant for all conditions tested (P < 0.001).
For analysis of immunohistochemical data, celiac cases were compared with controls using exact Wilcoxon rank sum tests.
Online supplemental material. Fig. S1 shows dose-dependent inhibition by AACOCF3 (CF3) and rescue by AA of NKG2D-mediated cytolysis. Fig. S2 shows the eff ect of cPLA2 inhibition by AACOCF3 (CF3) on granzyme and perforin expression in IE-and PB-CTLs. Fig. S3 shows that NKG2D stimulation induces perinuclear cPLA2 translocation and cPLA2 activity in IE-and PB-CTLs in a time-dependent manner. Fig. S4 shows that NKG2D and IL-15 induce cPLA2 phosphorylation in eff ector, but not resting, peripheral blood CTL. Fig. S5 shows that NKG2D induces notably lower levels of calcium release than the TCR in CTLs. A supplemental materials and methods is also provided. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20071887/DC1.
